Semaglutide

Ozempic, Wegovy, Rybelsus

Grade A: Approved and proven

TL;DR: Semaglutide has the broadest and most robust human evidence base among GLP-1 receptor agonists currently approved for weight management and type 2 diabetes. The STEP clinical trial program, comprising multiple large phase 3 randomized controlled trials, demonstrated clinically meaningful weight loss in adults with obesity or overweight, with or without type 2 diabetes. The SELECT trial, a large cardiovascular outcomes trial in over 17,000 adults with preexisting cardiovascular disease and obesity but without diabetes, showed a significant reduction in major adverse cardiovascular events with once-weekly subcutaneous semaglutide 2.4 mg versus placebo. Oral semaglutide (Rybelsus) is approved for type 2 diabetes, and a 25 mg oral formulation of Wegovy received FDA approval in December 2025 as the first oral GLP-1 for chronic weight management. Evidence is robust across multiple indications but weight regain after discontinuation is well documented, and very long-term safety data remain limited.

Key Takeaways

Grade A: Approved and proven
FDA approved: Approved as Ozempic (subcutaneous injection, type 2 diabetes), Wegovy (subcutaneous injection 2.4 mg and oral 25 mg tablet, chronic weight management and cardiovascular risk reduction in obesity), and Rybelsus (oral tablet, type 2 diabetes).
Compounding: FDA-approved; brand and generic forms available. Mass compounding from bulk API by 503A and 503B facilities was permitted during a declared shortage; the semaglutide shortage was resolved by FDA in February 2025 and enforcement grace periods for compounders ended by May 2025. As of June 2026, mass compounding of semaglutide injection is prohibited; FDA proposed in April 2026 to formally exclude semaglutide from the 503B Bulks List. Narrow 503A exceptions may apply for documented patient-specific clinical need.

Semaglutide chemical structure — Structure via PubChem CID 56843331

Mechanism

Semaglutide is a GLP-1 receptor agonist that stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central and peripheral GLP-1 receptor activation.

Evidence

Semaglutide has the broadest and most robust human evidence base among GLP-1 receptor agonists currently approved for weight management and type 2 diabetes. The STEP clinical trial program, comprising multiple large phase 3 randomized controlled trials, demonstrated clinically meaningful weight loss in adults with obesity or overweight, with or without type 2 diabetes. The SELECT trial, a large cardiovascular outcomes trial in over 17,000 adults with preexisting cardiovascular disease and obesity but without diabetes, showed a significant reduction in major adverse cardiovascular events with once-weekly subcutaneous semaglutide 2.4 mg versus placebo. Oral semaglutide (Rybelsus) is approved for type 2 diabetes, and a 25 mg oral formulation of Wegovy received FDA approval in December 2025 as the first oral GLP-1 for chronic weight management. Evidence is robust across multiple indications but weight regain after discontinuation is well documented, and very long-term safety data remain limited.

Safety and risks

Boxed warning: semaglutide causes thyroid C-cell tumors in rodents at clinically relevant exposures; human relevance is unknown but it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients should report any neck mass, hoarseness, difficulty swallowing, or shortness of breath promptly. Acute pancreatitis, including fatal hemorrhagic or necrotizing pancreatitis, has been reported; discontinue immediately if suspected and do not restart if confirmed. Gallbladder disease, including cholelithiasis and cholecystitis, occurs at a higher rate in treated patients than placebo and may require cholecystectomy. Acute kidney injury can occur secondary to dehydration from gastrointestinal side effects, particularly during dose escalation. Mean increases in resting heart rate of 1 to 4 beats per minute have been observed; sustained clinically relevant increases warrant discontinuation. The most common adverse reactions are nausea, diarrhea, vomiting, constipation, and abdominal pain.

Interactions

Risk of hypoglycemia increases when combined with insulin or insulin secretagogues such as sulfonylureas; dose reduction of those agents may be needed. Slowed gastric emptying may affect oral medication absorption.

Federal compounding status

FDA-approved drug as of 2026-06-02.

An FDA-approved drug that should be obtained as the licensed product. It is not a 503A bulk-substance candidate; compounding from bulk is limited under federal rules and generally permitted only during a declared shortage.

Federal status only, from public FDA records. State pharmacy-board rules vary and are not covered here. This is regulatory reporting, not legal advice. All compounds.

Compounding legality

FDA-approved; brand and generic forms available. Mass compounding from bulk API by 503A and 503B facilities was permitted during a declared shortage; the semaglutide shortage was resolved by FDA in February 2025 and enforcement grace periods for compounders ended by May 2025. As of June 2026, mass compounding of semaglutide injection is prohibited; FDA proposed in April 2026 to formally exclude semaglutide from the 503B Bulks List. Narrow 503A exceptions may apply for documented patient-specific clinical need.

Sources

Semaglutide is FDA approved. PeptideGrids presents evidence and regulatory status for informational purposes only. We do not sell, supply, source, or help anyone obtain this compound, and we provide no dosing or administration guidance. This is not medical advice; consult a licensed clinician. Full disclaimer.

Last reviewed June 1, 2026 by PeptideGrids editorial team (independently audited).